![Provectus Biopharmaceuticals, Inc. logo](/logos/PVCT.webp)
Provectus Biopharmaceuticals, Inc.
OTC:PVCT
Overview | Financials
Company Name | Provectus Biopharmaceuticals, Inc. |
Symbol | PVCT |
Currency | USD |
Price | 0.149 |
Market Cap | 62,550,728 |
Dividend Yield | 0% |
52-week-range | 0.052 - 0.19 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Eric A. Wachter |
Website | https://www.provectusbio.com |
An error occurred while fetching data.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver;
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD